The CARs consist of an anti-CD22 single-chain variable fragment（scFv）, a portion of the human CD137（4-1BB） molecule, and the intracellular component of the human CD3ζ molecule. Prior to CAR-T cell infusion, the patients will be subjected to preconditioning treatment. After CAR-T cell infusion, the patients will be evaluated for adverse reactions and efficacy.~The Main research objectives:~To evaluate the safety and efficacy of CD22CAR-T in patients with recurrent or refractory B-ALL~The Secondary research objectives:~To investigate the cytokinetic characteristics of CD22CAR-T in patients with recurrent or refractory B-ALL
This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD22 CAR-T cell in the treatment of recurrent or refractory B-ALL